DualityBio Expands its Collaboration with BioNTech to Advance the Development of DB-1305 for Solid Tumors
Shots:
- Duality Biologics expands their Apr 2023 collaboration with BioNTech SE to develop, manufacture and commercialize DB-1305 globally, excl. Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region. DB-1305 is currently being studied in the P-I/II trial for solid tumors
- Under the terms of the agreement, DualityBio will receive up front & is eligible to receive additional development, regulatory and commercial milestones along with royalties on net sales of DB-1305
- BioNTech will hold commercial rights globally while DualityBio will retain commercial rights for Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region
Ref: Prnewswire | Image: DualityBio
Related News:- BeiGene Collaborated with DualityBio to Advance Differentiated Antibody Drug Conjugate Therapy for Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
